Elbit Imaging Ltd. (EMITF)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist Elbit Imaging Ltd. (EMITF) ein Healthcare-Unternehmen mit einer Bewertung von 0. Bewertet mit 42/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 18. März 2026Elbit Imaging Ltd. (EMITF) Gesundheitswesen & Pipeline-Uebersicht
Elbit Imaging Ltd. operates in the healthcare sector, developing and marketing non-invasive therapeutic medical systems and stem cell-based products. The company also has real estate interests in India, reflecting a diversified business model within a small-cap framework and OTC market presence.
Investmentthese
Elbit Imaging Ltd. presents a speculative investment opportunity due to its presence in the medical device and stem cell therapy sectors, coupled with its real estate ventures in India. With a market capitalization of $0.02 billion and a negative P/E ratio of -4.98, the company's financial performance indicates challenges in achieving profitability. Growth catalysts may include advancements in its therapeutic medical systems and successful real estate sales in India. However, the company's OTC listing and limited financial disclosure pose significant risks. The company's beta of 0.24 suggests low volatility relative to the market. Investors should carefully consider the risks associated with OTC-listed companies and the uncertainties surrounding Elbit Imaging's diverse business activities before investing.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $0.02 billion indicates a micro-cap company with limited resources.
- Negative P/E ratio of -4.98 reflects current unprofitability.
- Beta of 0.24 suggests lower volatility compared to the overall market.
- No dividend yield, indicating that the company is not returning profits to shareholders.
- The company operates in both the healthcare (medical devices and stem cell therapies) and real estate sectors, diversifying its business interests.
Wettbewerber & Vergleichsunternehmen
Staerken
- Proprietary medical technologies.
- Diversified business interests (healthcare and real estate).
- Global distribution network.
- Expertise in stem cell-based therapies.
Schwaechen
- Small market capitalization.
- Negative P/E ratio indicating unprofitability.
- OTC market listing.
- Limited financial disclosure.
Katalysatoren
- Upcoming: Potential regulatory approvals for new medical devices in key markets.
- Ongoing: Expansion of distribution network for therapeutic medical systems.
- Ongoing: Progress in real estate development projects in India.
- Ongoing: Advancements in stem cell therapy research and development.
Risiken
- Potential: Competition from larger medical device companies.
- Potential: Regulatory hurdles for medical devices and stem cell therapies.
- Ongoing: Economic and political risks in India affecting real estate ventures.
- Ongoing: Limited access to capital due to small market capitalization.
- Ongoing: OTC market listing and limited financial disclosure.
Wachstumschancen
- Expansion of Therapeutic Medical Systems: The market for non-invasive therapeutic medical systems is growing as patients seek less invasive treatment options. Elbit Imaging can capitalize on this trend by expanding its product offerings and distribution network. The global market for medical devices is projected to reach $600 billion by 2028, offering a substantial opportunity for growth. Timeline: Ongoing.
- Advancements in Stem Cell Therapies: The stem cell therapy market is experiencing rapid growth due to its potential to treat a wide range of diseases. Elbit Imaging can invest in research and development to create new stem cell-based therapies and expand its market share. The global stem cell therapy market is expected to reach $17 billion by 2025. Timeline: Ongoing.
- Real Estate Development in India: India's real estate market is experiencing growth, driven by urbanization and increasing disposable incomes. Elbit Imaging can leverage its real estate holdings in India to generate revenue through property sales and development projects. The Indian real estate market is projected to reach $1 trillion by 2030. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Elbit Imaging can pursue strategic partnerships and acquisitions to expand its product portfolio, geographic reach, and technological capabilities. Collaborating with other companies in the medical device and stem cell therapy sectors can accelerate innovation and market penetration. Timeline: Ongoing.
- Regulatory Approvals and Market Access: Obtaining regulatory approvals for its medical devices and stem cell therapies in key markets is crucial for Elbit Imaging's growth. Successfully navigating the regulatory landscape and securing market access in regions such as the United States, Europe, and Asia can significantly boost revenue and profitability. Timeline: Ongoing.
Chancen
- Expansion of non-invasive treatment market.
- Growth in stem cell therapy market.
- Real estate development opportunities in India.
- Strategic partnerships and acquisitions.
Risiken
- Competition from larger medical device companies.
- Regulatory hurdles for medical devices and stem cell therapies.
- Economic and political risks in India.
- Limited access to capital.
Wettbewerbsvorteile
- Proprietary medical technologies for non-invasive treatments.
- Expertise in stem cell-based medical products.
- Established distribution network in multiple regions.
- Real estate holdings in India.
Ueber EMITF
Elbit Imaging Ltd., established in 1996 and headquartered in Petach Tikva, Israel, operates primarily in the healthcare sector, focusing on the development, production, and marketing of therapeutic medical systems. These systems are designed for non-invasive treatments using ultrasound beam and magnetic resonance imaging technologies. The company's medical systems are distributed across North and South America, Europe, Asia, and Oceania. In addition to its medical systems, Elbit Imaging offers medical products based on stem cells derived from umbilical cord blood, intended for bone marrow transplantation in patients with leukemia, lymphoma, non-malignant blood diseases, and metabolic genetic diseases. Beyond its healthcare activities, Elbit Imaging is also involved in real estate, specifically the sale of plots and villas in India, diversifying its revenue streams and business interests. The company's small size and OTC market listing reflect its position as a niche player with a diverse portfolio.
Was das Unternehmen tut
- Develops therapeutic medical systems for non-invasive treatments.
- Produces and markets medical systems using ultrasound beam and magnetic resonance imaging.
- Offers medical products based on stem cells derived from umbilical cord blood.
- Focuses on treatments for leukemia, lymphoma, and other blood diseases.
- Engages in the sale of plots and villas in India.
- Distributes medical systems in North and South America, Europe, Asia, and Oceania.
Geschaeftsmodell
- Generates revenue from the sale of therapeutic medical systems.
- Earns income from the sale of stem cell-based medical products.
- Derives revenue from real estate sales in India.
Branchenkontext
Elbit Imaging Ltd. operates within the medical device and stem cell therapy industries, which are characterized by rapid technological advancements and stringent regulatory requirements. The company also has exposure to the Indian real estate market. The medical device industry is projected to grow, driven by an aging population and increasing demand for non-invasive treatments. The stem cell therapy market is also expected to expand, fueled by advancements in regenerative medicine. However, Elbit Imaging faces competition from larger, more established players such as ASAPF, BTCY, GTHP, IPDQF, and ISCNF. The company's success depends on its ability to innovate and navigate the regulatory landscape effectively.
Wichtige Kunden
- Hospitals and medical centers.
- Oncology clinics.
- Patients requiring non-invasive treatments.
- Individuals seeking stem cell-based therapies.
- Real estate buyers in India.
Finanzdaten
Chart & Info
Elbit Imaging Ltd. (EMITF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Highs On Tuesday
· 24. März 2020
-
Stocks That Hit 52-Week Lows On Friday
· 16. Aug. 2019
-
Stocks Which Set New 52-Week Low Yesterday, October 31st
· 1. Nov. 2018
-
Stocks Which Set New 52-Week Low Friday, October 26th
· 29. Okt. 2018
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer EMITF.
Kursziele
Wall-Street-Kurszielanalyse fuer EMITF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von EMITF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Aktuelle Nachrichten
Fuehrung: Eran Mazor
CEO
Eran Mazor serves as the CEO of Elbit Imaging Ltd., overseeing the company's operations in the medical device and real estate sectors. His background includes experience in managing small teams and navigating the challenges of a micro-cap company. He is responsible for the strategic direction of the company, focusing on growth opportunities in the healthcare and real estate markets. He manages a team of 3 employees.
Erfolgsbilanz: Under Eran Mazor's leadership, Elbit Imaging has continued to develop and market its therapeutic medical systems and stem cell-based products. He has also overseen the company's real estate activities in India. His tenure has focused on maintaining the company's operations and exploring opportunities for growth within its niche markets.
EMITF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that may not meet the minimum financial standards or have chosen not to comply with the reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, making it difficult to assess their financial health and operational performance. Unlike NYSE or NASDAQ-listed companies, OTC Other firms face fewer regulations, leading to increased risks for investors due to potential lack of transparency and liquidity.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure due to OTC Other listing.
- Low liquidity and wide bid-ask spreads.
- Potential for price manipulation and fraud.
- Higher risk of delisting or trading suspension.
- Lack of regulatory oversight compared to NYSE or NASDAQ.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Check for any red flags, such as lawsuits or regulatory actions.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Company has been in operation since 1996.
- Focus on medical device and stem cell therapy sectors.
- Global distribution network for medical systems.
- Involvement in real estate activities in India.
Elbit Imaging Ltd. Aktie: Wichtige Fragen beantwortet
What are the key factors to evaluate for EMITF?
Elbit Imaging Ltd. (EMITF) currently holds an AI score of 42/100, indicating low score. Key strength: Proprietary medical technologies.. Primary risk to monitor: Potential: Competition from larger medical device companies.. This is not financial advice.
How frequently does EMITF data refresh on this page?
EMITF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven EMITF's recent stock price performance?
Recent price movement in Elbit Imaging Ltd. (EMITF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary medical technologies.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider EMITF overvalued or undervalued right now?
Determining whether Elbit Imaging Ltd. (EMITF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying EMITF?
Before investing in Elbit Imaging Ltd. (EMITF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding EMITF to a portfolio?
Potential reasons to consider Elbit Imaging Ltd. (EMITF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary medical technologies.. Additionally: Diversified business interests (healthcare and real estate).. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of EMITF?
Yes, most major brokerages offer fractional shares of Elbit Imaging Ltd. (EMITF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track EMITF's earnings and financial reports?
Elbit Imaging Ltd. (EMITF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for EMITF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available company data and may be limited due to the company's OTC listing.
- AI analysis pending for EMITF.